| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 6, 2026 | ±4.1% | -1.1% | over-priced |
| November 5, 2025 | ±5.6% | +4.0% | over-priced |
| April 30, 2025 | ±4.7% | -1.5% | over-priced |
| November 6, 2024 | ±3.6% | -3.2% | over-priced |
| July 31, 2024 | ±3.2% | +1.3% | over-priced |
| May 1, 2024 | ±4.4% | -1.1% | over-priced |
| November 1, 2023 | ±4.7% | -3.0% | over-priced |
| August 2, 2023 | ±3.1% | -2.5% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $2.34 | $1.4B | $329M |
| Q4 FY2025 | $-3.88 | $1.4B | $-402M |
| Q3 FY2025 | $-1.72 | $1.3B | $-148M |
| Q2 FY2025 | — | $0 | $0 |
Albemarle Corporation (ALB) reports in 123 days, with the next report estimated for October 14, 2026. Across the last 8 reports, options priced an average ±4.2% earnings move while the stock actually moved 2.2% on average — the market has systematically over-priced ALB's earnings risk. Fundamentals into the print: EPS up 0.0% year-over-year, revenue up 32.7%. QuantLogix's live 5-factor engine currently reads ALB as a buy at 61/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →